Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on August 7, 2025
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial of claseprubart …
Rapid7 Announces Second Quarter 2025 Financial Results
Annualized recurring revenue (“ARR”) of $841 million, an increase of 3% year-over-year Total revenue of $214 million, up 3% year-over-year; Product subscriptions revenue of $208 million, up 4% year-over-year GAAP operating income of $3.5 million; Non-GAAP …
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 …
Ascendis Pharma Reports Second Quarter 2025 Financial Results
– Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® ( …
Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights
TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to expand the therapeutic breadth …
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years. Received the …
Nephros Announces Strong Second Quarter Financial Results
SOUTH ORANGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June …
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs
- Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START’ study of …
GigaCloud Technology Inc Announces Second Quarter and Six Months Ended June 30, 2025 Financial Results
EL MONTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced financial results for the …
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital
BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain disorders, today announces the appointment of Tim Scannell, former President …
DataCapable Appoints Duke Energy Veteran Sandy Buzzard to Transform Utility Customer Engagement
HOUSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) -- When the power goes out, every second matters. That’s why DataCapable, the utility technology company redefining outage detection and response, has made a pivotal hire that underscores its commitment to customer- …
Meera Atkins, MD, MBA, FACOG Joins Lyric as Chief Medical Officer
Philadelphia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lyric, a market leading, AI-first healthcare technology company, today announced the appointment of Meera Kataria Atkins, MD, MBA, FACOG as its first-ever Chief Medical Officer. The creation of this executive …
Stripe Joins Odoo Connect 2025 as a Key Technology Partner
Odoo previews its September event agenda and speaker lineup in San Francisco SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Odoo, the leading open-source provider of enterprise resource planning (ERP) and customer relationship management (CRM) software, …
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events amongst the first 35 patients completing the trial suggests …
IGEL Expands Zero Trust Capabilities with Zscaler Client Connector on IGEL App Portal
FORT LAUDERDALE, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- IGEL, the secure endpoint OS platform fit for purpose in the modern enterprise, today announced that the Zscaler Client Connector (ZCC) is now available via the IGEL App Portal. With this new …
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a …
Genmab Announces Financial Results for the First Half of 2025
August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R2 in patients with relapsed or refractory …